Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Takeda Pharmaceuticals
Current Parent Company: Takeda Pharmaceutical
Penalty: $21,350,000
Year: 2023
Date: August 8, 2023
Offense Group: government-contracting-related offenses
Primary Offense: False Claims Act and related
Secondary Offense: kickbacks and bribery
Violation Description: The Office of the Attorney General's Civil Medicaid Fraud Division settled an enforcement action brought under the Texas Medicaid Fraud Prevention Act against pharmaceutical drug manufacturers Baxter International Inc. and Takeda Pharmaceuticals (along with several Takeda subsidiaries).The settlement resolved allegations that the drug manufacturers violated the Act by providing, directly or indirectly, nursing and reimbursement services to Texas Medicaid providers for certain pharmaceutical drugs, as well as by paying clinical nurse educators to refer or recommend the drug Vyvanse to providers from January 2014 to December 2015. Under the agreement, the drug manufacturers agreed to pay more than $42 million to settle the claims against the companies. The announcement did not indicate how much each company would pay. Here we assume Baxter and Takeda each paid half of the total.
Level of Government: state
Action Type: agency action
Agency: Texas Attorney General
Civil or Criminal Case: civil
Facility State: Texas
HQ Country of Current Parent: Japan
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.